Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $80 from $54 and keeps a Buy rating on the shares. The firm says the icotrokinra data set the standard for oral therapies in psoriasis and ulcerative colitis. Icotrokinra’s data in psoriasis and ulcerative colitis “were particularly impressive” and are going to lead to a paradigm shift in what’s possible with an oral therapy, the analyst tells investors in a research note.